Clinical standard-risk and intermediate-risk patients with MRD of @ % or higher at day @ of induction ( MRD high risk ) were randomly assigned ( @:@ ) to standard therapy ( treatment regimens A and B ) or augmented post-remission therapy ( regimen C ) .